Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

CAMBRIDGE, Mass., Jan. 15, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced initial results from its Phase 2a study of beloranib, a selective inhibitor of methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome (PWS), a severe form of genetic obesity.  These results showed improvements in body weight, hunger-related behaviors, and body composition, including reductions in body fat content and preserved lean body mass following four weeks of treatment. 

These changes were observed despite the increased caloric intake that was a component of this trial.  Known markers of beloranib response including those associated with cardiovascular disease risk were also improved, demonstrating that PWS patients responded to the molecular mechanism of beloranib.

"The results of this short-term proof-of-concept study are very promising and underscore our belief that beloranib has the potential to successfully treat this severe form of obesity.  To our knowledge, this study represents the largest placebo-controlled, randomized, multiple dose trial to date for obesity in this patient population, and these results bode well for further study of beloranib in patients with this devastating condition," said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen.

Similar to results seen in non-PWS obese patient populations, beloranib treatment in this study reduced body fat content by 8.1% vs. placebo in four weeks of treatment at the highest study dose of 1.8 mg, despite a 50% increased daily caloric allowance.  Hunger-related behaviors improved, and a trend towards overall improvement in body weight was seen, although this did not reach statistical significance, in part due to the fact that study was not powered to demonstrate these differ
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Hydrochloride listing their product specification, capacity, Production ...
(Date:9/19/2014)... , September 19, 2014 ... has announced the addition of the ... to their offering.      (Logo: ... been broadly classified into wide categories based ... for the treatment of different gynecological conditions ...
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... Inc. is pleased,to announce the dosing of the first ... study of AEG35156, a second generation antisense,therapeutic targeting XIAP, ... The study, made possible, in part, by funding ... 1-2, Multicenter, Open-Label Study,of the X- Linked Inhibitor of ...
... July 30 Anpath Group, Inc.,(OTC Bulletin Board: ... Inc. (ESI) announced that its EnviroTru(R),disinfectant has been ... Services (DMS) in the State of Florida. The ... LLC(TM) ( http://www.aworldofgreen.com ),worked with the ...
Cached Medicine Technology:Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 2Aegera Initiates a Fifth Phase 1 and 2 Clinical Trial for AEG35156 3Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 2Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida 3
(Date:9/21/2014)... Discount-Dress.com, a company that specializes ... its decision to implement a new shopping cart software ... across the world. Furthermore, the company has unveiled a ... , The new items come in fashionable designs; all ... to 56 percent off. "We are happy to release ...
(Date:9/21/2014)... High in the rugged Gore Range ... able-bodied athletes rafted the Colorado River, rode mountain bikes ... pursuit of outdoor adventure. At the September 12-14 ... Sports, disabilities proved to be no more than an ... stage event. , Each participating team of five athletes ...
(Date:9/21/2014)... 21, 2014 Recently, BambooIndustry.com, an experienced ... offer for its bamboo panels ( http://www.bambooindustry.com/products/bamboo-panel/ ). The ... all of them are available at discounted prices now, ... company’s discounted bamboo panels are available in ... quality materials. Each of them is finely manufactured by ...
(Date:9/21/2014)... According to latest National Vital Statistics Reports ... 1966 (10.5 births per 1,000 women in 2013). Since 2000, ... steadily by 2 percent per year. The birth rate for ... and over) also rose, the first such increase since 2008. ... times as many first births to women aged 35 and ...
(Date:9/20/2014)... (PRWEB) September 21, 2014 Diabetes ... Kenneth Pullman that is helping thousands of people learn ... symptoms without shots, pills, or prescriptions has caught the ... , “There are currently tens of millions of people ... 1 and Type 2 diabetes, and unfortunately, big pharma ...
Breaking Medicine News(10 mins):Health News:Discount-Dress.com Implements A New Shopping Cart Software And Provides New Beach Wedding Dresses 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2
... (ACP) today commended Congress for taking bipartisan action to ... by stabilizing physician payments through 2011. The College ... to enact legislation to provide longer-term stability in payments ... (SGR) formula. The legislation, passed unanimously ...
... News) -- There,s no scientific evidence that stricter testing ... federal food and nutrition programs would improve the safety ... Council report released Thursday. The authors based their ... Agriculture,s Agricultural Marketing Service,s (AMS) program, which is used ...
... Kathleen Doheny HealthDay Reporter , THURSDAY, Dec. ... drugs often prescribed to breast cancer patients, may ... according to a Canadian researcher. ,There have always ... Princess Margaret Hospital in Toronto, who is scheduled to ...
... new study shows that a new type of targeted ... good as surgery for patients aged 75 and older ... the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This ... Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), ...
... of the children,s television show Sesame Street, had improved ... by researchers at the Johns Hopkins Bloomberg School of ... had the greatest exposure to Jalan Sesama improved significantly ... social awareness, compared to those with no or low ...
... MI 9 December, 2010 The 19th International ... (CPMRC), an Elsevier company and leader in assisting healthcare ... focus on transformational leadership and feature advice from many ... Visa, Inc.. "The essence of transformation, real ...
Cached Medicine News:Health News:ACP commends Congress for preserving patient access by stopping scheduled Medicare SGR cuts 2Health News:No Scientific Proof Backing Stricter Tests of Ground Beef in School Lunches 2Health News:Certain Breast Cancer Drugs Linked With Heart Risks in Older Women 2Health News:Certain Breast Cancer Drugs Linked With Heart Risks in Older Women 3Health News:Non-invasive SRT as good as surgery for elderly patients with early lung cancer 2Health News:Sesame Street program improves development for children in Indonesia 2Health News:Transformation at top of agenda for CPMRC's annual conference in Jan. 2011 2
Post-Surgical compression garments...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Medicine Products: